Nesiritide (Natrecor) — CPB 0709 | AETNA Coverage Update

Aetna modified CPB 0709 covering nesiritide (Natrecor) coverage and billing, effective November 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0709 governing nesiritide (Natrecor) coverage for Aetna members. The policy affects HCPCS code J2325 (injection, nesiritide, 0.1 mg) and infusion administration codes CPT 96365–96368 and 96379. The update tightens the line between covered acute decompensated heart failure treatment and the long list of non-covered uses — and if your team isn't billing against the right ICD-10 codes, you're walking into a claim denial.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Nesiritide (Natrecor) — CPB 0709
Policy Code	CPB 0709
Change Type	Modified
Effective Date	November 26, 2025
Impact Level	Medium
Specialties Affected	Cardiology, Critical Care, Hospital Medicine, Infusion Services
Key Action	Confirm active ICD-10 codes map to acute decompensated CHF before submitting J2325 claims

---

Aetna Nesiritide Coverage Criteria and Medical Necessity Requirements 2025

The Aetna nesiritide coverage policy is narrow by design. Aetna covers nesiritide (Natrecor) under HCPCS code J2325 for one indication only: acute management of acutely decompensated congestive heart failure (CHF) in members who have dyspnea at rest or with minimal activity.

That's the entire covered universe. No outpatient optimization. No scheduled repeat dosing. No prophylactic use. Medical necessity hinges on two things being true simultaneously — the patient is acutely decompensated, and they have dyspnea at rest or with minimal activity.

Your ICD-10 coding has to reflect that acuity. Codes like I50.21 (acute systolic congestive heart failure), I50.23 (acute on chronic systolic congestive heart failure), I50.31 (acute diastolic congestive heart failure), I50.33 (acute on chronic diastolic congestive heart failure), I50.41 (acute combined systolic and diastolic congestive heart failure), and I50.43 (acute on chronic combined systolic and diastolic congestive heart failure) are the codes that support medical necessity here. Generic heart failure codes like I50.9 are a much weaker position for a J2325 claim.

CPB 0709 doesn't explicitly call out prior authorization requirements in its criteria language, but given the narrow indications and Aetna's general approach to infusion therapy coverage, confirm prior auth requirements for J2325 with the specific plan before administering. Prior auth workflows vary by product line — commercial, Medicare Advantage, and Medicaid products often differ. Reimbursement depends on having that authorization in place before the infusion starts.

---

Aetna Nesiritide Exclusions and Non-Covered Indications

This is where CPB 0709 gets specific — and where most billing risk sits. Aetna explicitly designates several uses as experimental, investigational, or unproven. These are not coverage edge cases. These are hard stops.

Intermittent or scheduled repetitive infusion is not covered when the patient is not acutely decompensated. This rules out outpatient optimization protocols and any "tune-up" infusion approach. If nesiritide billing shows up on an outpatient claim without acute decompensation diagnosis codes, expect denial.

Using nesiritide to enhance diuresis or improve renal function is not covered — full stop. This catches a real-world use pattern. Some clinicians use nesiritide as an adjunct when loop diuretics aren't producing adequate response. Aetna doesn't cover it for that purpose.

Prophylactic use for prevention of acute kidney injury is not covered. The renal ICD-10 codes included in the policy (N00.0–N20.9, N22–N26.1, N26.9–N29) appear in the policy's code range but map to non-covered indications. Don't let those renal codes anchor a J2325 claim — they're in the policy to define what's excluded, not what's covered.

Peri-operative nesiritide administration in members with left ventricular dysfunction undergoing cardiac surgery is not covered. This includes cardiac surgery adjunct protocols.

Adjuvant use following Fontan surgery is not covered. Pediatric cardiology teams billing for post-Fontan nesiritide use need to know this explicitly.

Subcutaneous administration — CPT 96372 — of B-type natriuretic peptide for heart failure treatment is not covered. The policy lists CPT 96372 in the "not covered" group for this reason. If your charge capture includes 96372 on nesiritide claims, remove it.

The real issue here is the diuresis and renal function exclusions. These are common off-label uses in hospitalized CHF patients, and they generate the most billing exposure. If your hospitalists or intensivists are ordering nesiritide for these purposes, the claim will not survive.

---

Coverage Indications at a Glance

---

Aetna Nesiritide Billing Guidelines and Action Items 2025

The effective date is November 26, 2025. Here's what your team needs to do before claims start hitting.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Nesiritide Under CPB 0709

Covered HCPCS Code (When Selection Criteria Are Met)

Code	Type	Description Copy
J2325	HCPCS	Injection, nesiritide, 0.1 mg

Not Covered CPT Code

Code	Type	Description	Reason Copy
96372	CPT	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	Subcutaneous administration of B-type natriuretic peptide for heart failure is not covered

Key ICD-10-CM Diagnosis Codes

Codes Supporting Covered Indications (Acute Decompensated CHF):

Renal Diagnosis Codes — Present in Policy to Define Non-Covered Indications:

Code	Description Copy
N00.0–N20.9	Glomerular and renal tubulo-interstitial diseases, acute kidney failure and chronic kidney disease
N22–N26.1	Glomerular and renal tubulo-interstitial diseases, acute kidney failure and chronic kidney disease
N26.9–N29	Glomerular and renal tubulo-interstitial diseases, acute kidney failure and chronic kidney disease

These renal codes appear in the CPB 0709 code table but define conditions for which nesiritide is not covered — specifically prophylactic use for acute kidney injury prevention and renal function enhancement. Do not use these as primary justification for J2325 claims.

---